ID   CD33_HUMAN              Reviewed;         364 AA.
AC   P20138; B4E3P8; C9JEN7; F8WAL2; Q8TD24;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   03-AUG-2022, entry version 214.
DE   RecName: Full=Myeloid cell surface antigen CD33;
DE   AltName: Full=Sialic acid-binding Ig-like lectin 3;
DE            Short=Siglec-3;
DE   AltName: Full=gp67;
DE   AltName: CD_antigen=CD33;
DE   Flags: Precursor;
GN   Name=CD33; Synonyms=SIGLEC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CD33M), AND VARIANT GLY-69.
RC   TISSUE=Premonocytic lymphoma;
RX   PubMed=3139766;
RA   Simmons D., Seed B.;
RT   "Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid
RT   progenitor cells.";
RL   J. Immunol. 141:2797-2800(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11943481; DOI=10.1016/s0378-1119(02)00432-8;
RA   Yousef G.M., Ordon M.H., Foussias G., Diamandis E.P.;
RT   "Genomic organization of the siglec gene locus on chromosome 19q13.4 and
RT   cloning of two new siglec pseudogenes.";
RL   Gene 286:259-270(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CD33M), AND ALTERNATIVE SPLICING.
RX   PubMed=16380601; DOI=10.1189/jlb.0205096;
RA   Hernandez-Caselles T., Martinez-Esparza M., Perez-Oliva A.B.,
RA   Quintanilla-Cecconi A.M., Garcia-Alonso A., Alvarez-Lopez D.M.,
RA   Garcia-Penarrubia P.;
RT   "A study of CD33 (SIGLEC-3) antigen expression and function on activated
RT   human T and NK cells: two isoforms of CD33 are generated by alternative
RT   splicing.";
RL   J. Leukoc. Biol. 79:46-58(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS VAL-14 AND
RP   ARG-304.
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CD33M), AND VARIANT GLY-69.
RC   TISSUE=Leukocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, AND SIALIC ACID-BINDING.
RX   PubMed=7718872;
RA   Freeman S.D., Kelm S., Barber E.K., Crocker P.R.;
RT   "Characterization of CD33 as a new member of the sialoadhesin family of
RT   cellular interaction molecules.";
RL   Blood 85:2005-2012(1995).
RN   [9]
RP   GLYCOSYLATION AT ASN-100, AND MUTAGENESIS OF ASN-100.
RX   PubMed=8702538; DOI=10.1074/jbc.271.31.18803;
RA   Sgroi D., Nocks A., Stamenkovic I.;
RT   "A single N-linked glycosylation site is implicated in the regulation of
RT   ligand recognition by the I-type lectins CD22 and CD33.";
RL   J. Biol. Chem. 271:18803-18809(1996).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT TYR-340 AND TYR-358, MUTAGENESIS OF TYR-358,
RP   AND INTERACTION WITH PTPN6.
RX   PubMed=10556798;
RX   DOI=10.1002/(sici)1521-4141(199911)29:11<3440::aid-immu3440>3.0.co;2-c;
RA   Ulyanova T., Blasioli J., Woodford-Thomas T.A., Thomas M.L.;
RT   "The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.";
RL   Eur. J. Immunol. 29:3440-3449(1999).
RN   [11]
RP   PHOSPHORYLATION AT TYR-340 AND TYR-358, INTERACTION WITH PTPN6 AND PTPN11,
RP   AND MUTAGENESIS OF TYR-340.
RX   PubMed=10206955; DOI=10.1074/jbc.274.17.11505;
RA   Taylor V.C., Buckley C.D., Douglas M., Cody A.J., Simmons D.L.,
RA   Freeman S.D.;
RT   "The myeloid-specific sialic acid-binding receptor, CD33, associates with
RT   the protein-tyrosine phosphatases, SHP-1 and SHP-2.";
RL   J. Biol. Chem. 274:11505-11512(1999).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10611343; DOI=10.1073/pnas.96.26.15091;
RA   Vitale C., Romagnani C., Falco M., Ponte M., Vitale M., Moretta A.,
RA   Bacigalupo A., Moretta L., Mingari M.C.;
RT   "Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or
RT   leukemic myeloid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:15091-15096(1999).
RN   [13]
RP   FUNCTION, PHOSPHORYLATION AT TYR-340 AND TYR-358, MUTAGENESIS OF TYR-340
RP   AND TYR-358, AND SUBUNIT.
RX   PubMed=10887109;
RA   Paul S.P., Taylor L.S., Stansbury E.K., McVicar D.W.;
RT   "Myeloid specific human CD33 is an inhibitory receptor with differential
RT   ITIM function in recruiting the phosphatases SHP-1 and SHP-2.";
RL   Blood 96:483-490(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=11320212; DOI=10.1073/pnas.091097198;
RA   Vitale C., Romagnani C., Puccetti A., Olive D., Costello R., Chiossone L.,
RA   Pitto A., Bacigalupo A., Moretta L., Mingari M.C.;
RT   "Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid
RT   leukemias: engagement of CD33 induces apoptosis of leukemic cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:5764-5769(2001).
RN   [15]
RP   FUNCTION.
RX   PubMed=15597323; DOI=10.1002/eji.200425273;
RA   Lajaunias F., Dayer J.M., Chizzolini C.;
RT   "Constitutive repressor activity of CD33 on human monocytes requires sialic
RT   acid recognition and phosphoinositide 3-kinase-mediated intracellular
RT   signaling.";
RL   Eur. J. Immunol. 35:243-251(2005).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH C1QA.
RX   PubMed=28325905; DOI=10.1038/s41598-017-00290-w;
RA   Son M., Diamond B., Volpe B.T., Aranow C.B., Mackay M.C.,
RA   Santiago-Schwarz F.;
RT   "Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory
RT   immunoreceptors and biological control of CD33/LAIR-1 expression.";
RL   Sci. Rep. 7:270-270(2017).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=28747436; DOI=10.1074/jbc.m117.799346;
RA   Siddiqui S.S., Springer S.A., Verhagen A., Sundaramurthy V.,
RA   Alisson-Silva F., Jiang W., Ghosh P., Varki A.;
RT   "The Alzheimer's disease-protective CD33 splice variant mediates adaptive
RT   loss of function via diversion to an intracellular pool.";
RL   J. Biol. Chem. 292:15312-15320(2017).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 21-232 IN COMPLEX WITH GALACTOSE,
RP   GLYCOSYLATION AT ASN-100; ASN-160; ASN-209 AND ASN-230, AND DISULFIDE
RP   BONDS.
RA   Dodd R.B., Meadows W., Qamar S., Johnson C.M., Kronenberg-Versteeg D.,
RA   St George-Hyslop P.;
RT   "Structure of ligand bound CD33 receptor associated with Alzheimer's
RT   disease.";
RL   Submitted (MAR-2016) to the PDB data bank.
CC   -!- FUNCTION: Sialic-acid-binding immunoglobulin-like lectin (Siglec) that
CC       plays a role in mediating cell-cell interactions and in maintaining
CC       immune cells in a resting state (PubMed:10611343, PubMed:15597323,
CC       PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and
CC       more avidly alpha-2,6-linked sialic acid-bearing glycans
CC       (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated
CC       glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs
CC       (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like
CC       kinases such as LCK (PubMed:28325905, PubMed:10887109). These
CC       phosphorylations provide docking sites for the recruitment and
CC       activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-
CC       2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these
CC       phosphatases regulate downstream pathways through dephosphorylation of
CC       signaling molecules (PubMed:10206955, PubMed:10887109). One of the
CC       repressive effect of CD33 on monocyte activation requires
CC       phosphoinositide 3-kinase/PI3K (PubMed:15597323).
CC       {ECO:0000269|PubMed:10206955, ECO:0000269|PubMed:10556798,
CC       ECO:0000269|PubMed:10611343, ECO:0000269|PubMed:10887109,
CC       ECO:0000269|PubMed:11320212, ECO:0000269|PubMed:15597323,
CC       ECO:0000269|PubMed:28325905, ECO:0000269|PubMed:7718872}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:10887109). Interacts with
CC       PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation (PubMed:10556798,
CC       PubMed:10206955). Interacts with C1QA (via C-terminus); this
CC       interaction activates CD33 inhibitory motifs (PubMed:28325905).
CC       {ECO:0000269|PubMed:10206955, ECO:0000269|PubMed:10556798,
CC       ECO:0000269|PubMed:10887109, ECO:0000269|PubMed:28325905}.
CC   -!- INTERACTION:
CC       P20138; O95393: BMP10; NbExp=3; IntAct=EBI-3906571, EBI-3922513;
CC       P20138; Q07325: CXCL9; NbExp=3; IntAct=EBI-3906571, EBI-3911467;
CC       P20138; O43169: CYB5B; NbExp=3; IntAct=EBI-3906571, EBI-1058710;
CC       P20138; P50402: EMD; NbExp=3; IntAct=EBI-3906571, EBI-489887;
CC       P20138; Q96F15: GIMAP5; NbExp=3; IntAct=EBI-3906571, EBI-6166686;
CC       P20138; Q15323: KRT31; NbExp=6; IntAct=EBI-3906571, EBI-948001;
CC       P20138; Q92764: KRT35; NbExp=3; IntAct=EBI-3906571, EBI-1058674;
CC       P20138; Q6A162: KRT40; NbExp=3; IntAct=EBI-3906571, EBI-10171697;
CC       P20138; Q06124: PTPN11; NbExp=5; IntAct=EBI-3906571, EBI-297779;
CC       P20138; P29350: PTPN6; NbExp=10; IntAct=EBI-3906571, EBI-78260;
CC       P20138; Q9NS64: RPRM; NbExp=3; IntAct=EBI-3906571, EBI-1052363;
CC       P20138; P06702: S100A9; NbExp=5; IntAct=EBI-3906571, EBI-1055001;
CC       P20138; O00767: SCD; NbExp=3; IntAct=EBI-3906571, EBI-2684237;
CC       P20138; Q9UPZ6: THSD7A; NbExp=3; IntAct=EBI-3906571, EBI-310962;
CC       P20138; Q969X1: TMBIM1; NbExp=3; IntAct=EBI-3906571, EBI-2820569;
CC       P20138; Q9NV29: TMEM100; NbExp=3; IntAct=EBI-3906571, EBI-8644968;
CC       P20138; Q9BU79: TMEM243; NbExp=3; IntAct=EBI-3906571, EBI-12887458;
CC       P20138; Q9H2S6-2: TNMD; NbExp=3; IntAct=EBI-3906571, EBI-12003398;
CC       P20138; Q5BVD1: TTMP; NbExp=3; IntAct=EBI-3906571, EBI-10243654;
CC       P20138; Q9Y5Z9: UBIAD1; NbExp=3; IntAct=EBI-3906571, EBI-2819725;
CC   -!- SUBCELLULAR LOCATION: [Isoform CD33M]: Cell membrane
CC       {ECO:0000269|PubMed:10611343, ECO:0000269|PubMed:28747436}; Single-pass
CC       type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform CD33m]: Peroxisome
CC       {ECO:0000269|PubMed:28747436}. Note=CD33m isoform does not localize to
CC       cell surfaces but instead accumulates in peroxisomes.
CC       {ECO:0000269|PubMed:28747436}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=CD33M;
CC         IsoId=P20138-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P20138-2; Sequence=VSP_045364;
CC       Name=CD33m;
CC         IsoId=P20138-3; Sequence=VSP_046172;
CC   -!- TISSUE SPECIFICITY: Monocytic/myeloid lineage cells. In the brain, CD33
CC       is mainly expressed on microglial cells.
CC   -!- DOMAIN: Contains 2 copies of a cytoplasmic motif that is referred to as
CC       the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is
CC       involved in modulation of cellular responses. The phosphorylated ITIM
CC       motif can bind the SH2 domain of several SH2-containing phosphatases.
CC   -!- PTM: Glycosylated. Glycosylation at Asn-100 is critical for regulating
CC       ligand recognition. {ECO:0000269|PubMed:8702538}.
CC   -!- PTM: Phosphorylation of Tyr-340 is involved in binding to PTPN6 and
CC       PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. LCK
CC       phosphorylates Tyr-340 efficiently and Tyr-358 to a lesser extent.
CC       {ECO:0000269|PubMed:10206955, ECO:0000269|PubMed:10556798,
CC       ECO:0000269|PubMed:10887109}.
CC   -!- MISCELLANEOUS: [Isoform CD33m]: Mostly detected on NKL and myeloid cell
CC       lines but poorly expressed on B-cell lines and T-lymphocytes.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily. SIGLEC (sialic
CC       acid binding Ig-like lectin) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Siglec-3;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_270";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23197; AAA51948.1; ALT_SEQ; mRNA.
DR   EMBL; AY040541; AAK83654.1; -; Genomic_DNA.
DR   EMBL; AY162464; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK304810; BAG65560.1; -; mRNA.
DR   EMBL; AC063977; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471135; EAW71996.1; -; Genomic_DNA.
DR   EMBL; BC028152; AAH28152.1; -; mRNA.
DR   CCDS; CCDS33084.1; -. [P20138-1]
DR   CCDS; CCDS46157.1; -. [P20138-3]
DR   CCDS; CCDS54299.1; -. [P20138-2]
DR   PIR; A30521; A30521.
DR   RefSeq; NP_001076087.1; NM_001082618.1. [P20138-3]
DR   RefSeq; NP_001171079.1; NM_001177608.1. [P20138-2]
DR   RefSeq; NP_001763.3; NM_001772.3. [P20138-1]
DR   RefSeq; XP_011525834.1; XM_011527532.2. [P20138-1]
DR   PDB; 5IHB; X-ray; 2.24 A; A/B/C/D=21-232.
DR   PDB; 5J06; X-ray; 2.66 A; A/B/C/D=21-232.
DR   PDB; 5J0B; X-ray; 2.48 A; A/B/C/D=21-232.
DR   PDB; 6D48; X-ray; 1.78 A; E/F/G/H=18-143.
DR   PDB; 6D49; X-ray; 1.80 A; A/B=18-143.
DR   PDB; 6D4A; X-ray; 1.75 A; A/B=18-143.
DR   PDB; 6TL8; X-ray; 2.80 A; A/B/C/D=1-16.
DR   PDB; 7AW6; X-ray; 1.95 A; A/B=21-232.
DR   PDBsum; 5IHB; -.
DR   PDBsum; 5J06; -.
DR   PDBsum; 5J0B; -.
DR   PDBsum; 6D48; -.
DR   PDBsum; 6D49; -.
DR   PDBsum; 6D4A; -.
DR   PDBsum; 6TL8; -.
DR   PDBsum; 7AW6; -.
DR   AlphaFoldDB; P20138; -.
DR   SMR; P20138; -.
DR   BioGRID; 107383; 48.
DR   IntAct; P20138; 33.
DR   MINT; P20138; -.
DR   STRING; 9606.ENSP00000262262; -.
DR   ChEMBL; CHEMBL1842; -.
DR   DrugBank; DB06318; AVE9633.
DR   DrugBank; DB00056; Gemtuzumab ozogamicin.
DR   DrugCentral; P20138; -.
DR   GuidetoPHARMACOLOGY; 2601; -.
DR   UniLectin; P20138; -.
DR   GlyGen; P20138; 8 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P20138; -.
DR   PhosphoSitePlus; P20138; -.
DR   BioMuta; CD33; -.
DR   DMDM; 116241290; -.
DR   EPD; P20138; -.
DR   jPOST; P20138; -.
DR   MassIVE; P20138; -.
DR   PaxDb; P20138; -.
DR   PeptideAtlas; P20138; -.
DR   PRIDE; P20138; -.
DR   ProteomicsDB; 30518; -.
DR   ProteomicsDB; 53725; -. [P20138-1]
DR   ProteomicsDB; 9878; -.
DR   ABCD; P20138; 5 sequenced antibodies.
DR   Antibodypedia; 4419; 2695 antibodies from 51 providers.
DR   CPTC; P20138; 5 antibodies.
DR   DNASU; 945; -.
DR   Ensembl; ENST00000262262.5; ENSP00000262262.3; ENSG00000105383.15. [P20138-1]
DR   Ensembl; ENST00000391796.7; ENSP00000375673.2; ENSG00000105383.15. [P20138-2]
DR   Ensembl; ENST00000421133.6; ENSP00000410126.1; ENSG00000105383.15. [P20138-3]
DR   GeneID; 945; -.
DR   KEGG; hsa:945; -.
DR   MANE-Select; ENST00000262262.5; ENSP00000262262.3; NM_001772.4; NP_001763.3.
DR   UCSC; uc010eos.2; human. [P20138-1]
DR   CTD; 945; -.
DR   DisGeNET; 945; -.
DR   GeneCards; CD33; -.
DR   HGNC; HGNC:1659; CD33.
DR   HPA; ENSG00000105383; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 159590; gene.
DR   neXtProt; NX_P20138; -.
DR   OpenTargets; ENSG00000105383; -.
DR   PharmGKB; PA26210; -.
DR   VEuPathDB; HostDB:ENSG00000105383; -.
DR   eggNOG; ENOG502S41V; Eukaryota.
DR   GeneTree; ENSGT01040000240469; -.
DR   HOGENOM; CLU_102212_0_0_1; -.
DR   InParanoid; P20138; -.
DR   OMA; EGAIVSW; -.
DR   PhylomeDB; P20138; -.
DR   TreeFam; TF332441; -.
DR   PathwayCommons; P20138; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; P20138; -.
DR   SIGNOR; P20138; -.
DR   BioGRID-ORCS; 945; 10 hits in 1077 CRISPR screens.
DR   ChiTaRS; CD33; human.
DR   GenomeRNAi; 945; -.
DR   Pharos; P20138; Tclin.
DR   PRO; PR:P20138; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P20138; protein.
DR   Bgee; ENSG00000105383; Expressed in monocyte and 115 other tissues.
DR   ExpressionAtlas; P20138; baseline and differential.
DR   Genevisible; P20138; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:ARUK-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0033691; F:sialic acid binding; IMP:ARUK-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0098609; P:cell-cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0002765; P:immune response-inhibiting signal transduction; IDA:UniProtKB.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; IMP:ARUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IMP:ARUK-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; IMP:ARUK-UCL.
DR   GO; GO:0150102; P:negative regulation of monocyte activation; IDA:ARUK-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:ARUK-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:1903615; P:positive regulation of protein tyrosine phosphatase activity; IMP:ARUK-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 2.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Lectin; Membrane;
KW   Peroxisome; Phosphoprotein; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000255"
FT   CHAIN           18..364
FT                   /note="Myeloid cell surface antigen CD33"
FT                   /id="PRO_0000014878"
FT   TOPO_DOM        18..259
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        260..282
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        283..364
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          19..135
FT                   /note="Ig-like V-type"
FT   DOMAIN          145..228
FT                   /note="Ig-like C2-type"
FT   REGION          290..364
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           338..343
FT                   /note="ITIM motif 1"
FT   MOTIF           356..361
FT                   /note="ITIM motif 2"
FT   COMPBIAS        347..364
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         119
FT                   /ligand="N-acetylneuraminate"
FT                   /ligand_id="ChEBI:CHEBI:35418"
FT                   /evidence="ECO:0000250"
FT   BINDING         154
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0007744|PDB:5J0B"
FT   MOD_RES         340
FT                   /note="Phosphotyrosine; by LCK"
FT                   /evidence="ECO:0000269|PubMed:10206955,
FT                   ECO:0000269|PubMed:10556798, ECO:0000269|PubMed:10887109"
FT   MOD_RES         358
FT                   /note="Phosphotyrosine; by LCK"
FT                   /evidence="ECO:0000269|PubMed:10206955,
FT                   ECO:0000269|PubMed:10556798, ECO:0000269|PubMed:10887109"
FT   CARBOHYD        100
FT                   /note="N-linked (GalNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8702538,
FT                   ECO:0007744|PDB:5IHB, ECO:0007744|PDB:5J06,
FT                   ECO:0007744|PDB:5J0B"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        160
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0007744|PDB:5IHB, ECO:0007744|PDB:5J06,
FT                   ECO:0007744|PDB:5J0B"
FT   CARBOHYD        209
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0007744|PDB:5IHB, ECO:0007744|PDB:5J06,
FT                   ECO:0007744|PDB:5J0B"
FT   CARBOHYD        230
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0007744|PDB:5J06"
FT   DISULFID        36..169
FT                   /evidence="ECO:0000269|Ref.18"
FT   DISULFID        41..101
FT                   /evidence="ECO:0000269|Ref.18"
FT   DISULFID        163..212
FT                   /evidence="ECO:0000269|Ref.18"
FT   VAR_SEQ         13..139
FT                   /note="Missing (in isoform CD33m)"
FT                   /evidence="ECO:0000303|PubMed:16380601"
FT                   /id="VSP_046172"
FT   VAR_SEQ         309..364
FT                   /note="KHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSE
FT                   VRTQ -> VR (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045364"
FT   VARIANT         14
FT                   /note="A -> V (in dbSNP:rs12459419)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_049904"
FT   VARIANT         22
FT                   /note="W -> R (in dbSNP:rs35814802)"
FT                   /id="VAR_049905"
FT   VARIANT         69
FT                   /note="R -> G (in dbSNP:rs2455069)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:3139766"
FT                   /id="VAR_028260"
FT   VARIANT         128
FT                   /note="S -> N (in dbSNP:rs34919259)"
FT                   /id="VAR_049906"
FT   VARIANT         202
FT                   /note="R -> W (in dbSNP:rs4082929)"
FT                   /id="VAR_028261"
FT   VARIANT         242
FT                   /note="I -> L (in dbSNP:rs988337)"
FT                   /id="VAR_028262"
FT   VARIANT         243
FT                   /note="F -> L (in dbSNP:rs11882250)"
FT                   /id="VAR_028263"
FT   VARIANT         267
FT                   /note="V -> I (in dbSNP:rs58981829)"
FT                   /id="VAR_061319"
FT   VARIANT         294
FT                   /note="V -> L (in dbSNP:rs2271652)"
FT                   /id="VAR_028264"
FT   VARIANT         304
FT                   /note="G -> R (in dbSNP:rs35112940)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_049907"
FT   VARIANT         331
FT                   /note="T -> A (in dbSNP:rs35632246)"
FT                   /id="VAR_049908"
FT   MUTAGEN         100
FT                   /note="N->A: Significant loss of binding to peripheral
FT                   blood granulocytes."
FT                   /evidence="ECO:0000269|PubMed:8702538"
FT   MUTAGEN         340
FT                   /note="Y->A: Abolishes binding to PTPN6 and PTPN11.
FT                   Increases binding of red blood cells."
FT                   /evidence="ECO:0000269|PubMed:10206955"
FT   MUTAGEN         340
FT                   /note="Y->F: Complete loss of phosphorylation by LCK."
FT                   /evidence="ECO:0000269|PubMed:10887109"
FT   MUTAGEN         358
FT                   /note="Y->A,F: Reduces binding to PTPN6."
FT                   /evidence="ECO:0000269|PubMed:10556798"
FT   MUTAGEN         358
FT                   /note="Y->F: More than 50% loss of phosphorylation by LCK."
FT                   /evidence="ECO:0000269|PubMed:10887109"
FT   STRAND          22..25
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          27..32
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          41..44
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   HELIX           49..51
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          56..62
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   TURN            67..69
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          73..76
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   TURN            84..89
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          90..92
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   HELIX           110..112
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          114..122
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          125..128
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          134..139
FT                   /evidence="ECO:0007829|PDB:6D4A"
FT   STRAND          146..148
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   STRAND          159..164
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   STRAND          176..191
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   STRAND          194..199
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   HELIX           203..205
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   STRAND          209..215
FT                   /evidence="ECO:0007829|PDB:7AW6"
FT   STRAND          217..220
FT                   /evidence="ECO:0007829|PDB:5IHB"
FT   STRAND          222..228
FT                   /evidence="ECO:0007829|PDB:7AW6"
SQ   SEQUENCE   364 AA;  39825 MW;  1C73E588240FBAD8 CRC64;
     MPLLLLLPLL WAGALAMDPN FWLQVQESVT VQEGLCVLVP CTFFHPIPYY DKNSPVHGYW
     FREGAIISRD SPVATNKLDQ EVQEETQGRF RLLGDPSRNN CSLSIVDARR RDNGSYFFRM
     ERGSTKYSYK SPQLSVHVTD LTHRPKILIP GTLEPGHSKN LTCSVSWACE QGTPPIFSWL
     SAAPTSLGPR TTHSSVLIIT PRPQDHGTNL TCQVKFAGAG VTTERTIQLN VTYVPQNPTT
     GIFPGDGSGK QETRAGVVHG AIGGAGVTAL LALCLCLIFF IVKTHRRKAA RTAVGRNDTH
     PTTGSASPKH QKKSKLHGPT ETSSCSGAAP TVEMDEELHY ASLNFHGMNP SKDTSTEYSE
     VRTQ
//
